Conduit Pharmaceuticals Inc (CDT)
$0.12
Market is closed - opens 7 PM, 09 Sep 2024
Performance
- $0.12$0.13$0.12
0.0%
Downside
Day's Volatility :4.38%
Upside
4.38%
- $0.11$12.89$0.12
6.17%
Downside
52 Weeks Volatility :99.13%
Upside
99.07%
Returns
| Period | Conduit Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -95.65% | 0.0% |
6 Months | -95.34% | 0.0% |
1 Year | -98.81% | 0.0% |
3 Years | -98.81% | -22.3% |
Highlights
Market Capitalization | 12.0M |
Book Value | - $0.07 |
Earnings Per Share (EPS) | -0.08 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -322.02% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -0.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Conduit Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Conduit Pharmaceuticals Inc | -25.15% | -95.34% | -98.81% | -98.81% | -98.81% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Conduit Pharmaceuticals Inc | NA | NA | NA | 0.0 | 0.0 | -3.22 | NA | -0.07 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Conduit Pharmaceuticals Inc | NA | $12.0M | -98.81% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Company Information
Organization | Conduit Pharmaceuticals Inc |
Employees | 7 |
CEO | Dr. David Joszef Tapolczay |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$0.12
-0.8%
Keyarch Acquisition Corp
$0.12
-0.8%
Connexa Sports Technologies Inc
$0.12
-0.8%
Us Value Etf
$0.12
-0.8%
First Wave Biopharma Inc
$0.12
-0.8%
Global X Msci Next Emerging
$0.12
-0.8%
Fat Projects Acquisition Corp
$0.12
-0.8%
Capital Link Global Fintech
$0.12
-0.8%
Applied Uv Inc
$0.12
-0.8%